Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $7.6 million.

  • Cytek Biosciences' Accounts Payables rose 4162.18% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 4162.18%. This contributed to the annual value of $5.5 million for FY2024, which is 8235.49% up from last year.
  • As of Q3 2025, Cytek Biosciences' Accounts Payables stood at $7.6 million, which was up 4162.18% from $6.9 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Accounts Payables high stood at $7.6 million for Q3 2025, and its period low was $3.0 million during Q4 2023.
  • In the last 5 years, Cytek Biosciences' Accounts Payables had a median value of $5.0 million in 2022 and averaged $4.9 million.
  • Per our database at Business Quant, Cytek Biosciences' Accounts Payables crashed by 5433.4% in 2023 and then surged by 11476.03% in 2025.
  • Over the past 5 years, Cytek Biosciences' Accounts Payables (Quarter) stood at $3.0 million in 2021, then skyrocketed by 58.37% to $4.8 million in 2022, then crashed by 36.9% to $3.0 million in 2023, then skyrocketed by 82.35% to $5.5 million in 2024, then skyrocketed by 38.04% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $6.9 million for Q2 2025, and $6.2 million during Q1 2025.